Picard Medical Inc. (NYSE American: PMI) announced that a 29-year-old patient successfully received a donor heart transplant after living for more than four years supported by the SynCardia Total Artificial Heart.

The patient received the artificial heart implant on September 2, 2021, following severe biventricular heart failure. The device replaced both sides of the heart's pumping function and maintained circulation for 1,636 days until the patient underwent heart transplantation on February 24, 2026.

"The challenge in advanced heart failure is often the time required to find a suitable donor organ," said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical. "This case demonstrates how the SynCardia Total Artificial Heart can sustain critically ill patients for extended periods, allowing them to live at home while awaiting heart transplantation."

The SynCardia Total Artificial Heart serves as a bridge to transplant for patients with irreversible biventricular heart failure who cannot be supported with isolated left ventricular assist device therapy. The device replaces both ventricles and all four native heart valves.

More than 2,100 SynCardia Total Artificial Heart implants have been performed worldwide, with the longest documented patient support exceeding eight years. The device is approved by both the U.S. FDA and Health Canada.

Picard Medical is the parent company of SynCardia Systems LLC, which develops and manufactures the artificial heart technology. The SynCardia Total Artificial Heart has been implanted at hospitals across 27 countries.